.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Teva
Chubb
Healthtrust
Merck
US Department of Justice
Daiichi Sankyo
Colorcon
UBS
Fish and Richardson

Generated: June 29, 2017

DrugPatentWatch Database Preview

SOMAVERT Drug Profile

« Back to Dashboard

What is the patent landscape for Somavert, and when can generic versions of Somavert launch?

Somavert is a drug marketed by Pharmacia And Upjohn and is included in one NDA. There is one patent protecting this drug.

This drug has fifty patent family members in fifteen countries.

The generic ingredient in SOMAVERT is pegvisomant. One supplier is listed for this compound. Additional details are available on the pegvisomant profile page.

Summary for Tradename: SOMAVERT

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list15
Drug Prices:see details
DailyMed Link:SOMAVERT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 2003RXYesYes5,849,535► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-004Jul 31, 2014RXYesYes5,849,535► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-002Mar 25, 2003RXYesYes5,849,535► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003RXYesYes5,849,535► SubscribeY ► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-005Jul 31, 2014RXYesYes5,849,535► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SOMAVERT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 20035,681,809► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 20035,849,535► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 20035,958,879► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-002Mar 25, 20036,057,292► Subscribe
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 20036,583,115► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SOMAVERT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,022,711 Human growth hormone variants having enhanced affinity for human growth hormone receptor at site 1► Subscribe
6,040,136 Enrichment method for variant proteins with altered binding properties► Subscribe
5,750,373 Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants► Subscribe
5,955,346 Variants of human prolactin and human placeatal lactogen► Subscribe
5,821,047 Monovalent phage display► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SOMAVERT

Country Document Number Estimated Expiration
Germany69129154► Subscribe
European Patent Office0851925► Subscribe
Japan3765959► Subscribe
Japan2005065705► Subscribe
JapanH07503600► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SOMAVERT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB05/047United Kingdom► SubscribePRODUCT NAME: PEGVISOMANT, OPTIONALLY IN THE FORM OF A PEGYLATION VARIANT; REGISTRATION NO/DATE: EU/1/02/240/001 - 003 20021113
C0043France► SubscribePRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113
C029/2005Ireland► SubscribeSPC029/2005: 20061023, EXPIRES: 20171112
2005 00043Denmark► Subscribe
8Finland► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Dow
Julphar
Boehringer Ingelheim
Cipla
Mallinckrodt
Fish and Richardson
Farmers Insurance
Healthtrust
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot